{"filing":{"accession_number":"0001021771-26-000091","cik":"0001505497","ticker":"BRTX","company_name":"BioRestorative Therapies, Inc.","form":"8-K","filing_date":"2026-06-12","report_date":null,"primary_document":"brtx-20260612.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1505497/000102177126000091/brtx-20260612.htm"},"events":[{"id":10333,"run_id":9062,"accession_number":"0001021771-26-000091","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"BioRestorative Therapies entered into a $1,000,000 Revolving Loan Agreement with Bowery Group LLC on June 10, 2026, which includes lender rights to designate directors, representing a material change of control indicator and significant shift in governance and financial control.","company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","filing_date":"2026-06-12","form":"8-K","submitted_at":null,"items":[{"id":6623,"accession_number":"0001021771-26-000091","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The Company entered into a $1,000,000 Revolving Loan Agreement with Bowery Group LLC on June 10, 2026, a material definitive agreement disclosed under Item 1.01. While this is a financing arrangement rather than a traditional M\u0026A transaction, it represents a material change of control indicator given the Lender's right to designate directors (referenced in Item 5.02), suggesting a significant shift in governance and financial control that would affect a reasonable investor's assessment of the registrant.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:03:39.161296+00:00","company_name":"","ticker":null,"filing_date":""},{"id":6624,"accession_number":"0001021771-26-000091","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses the appointment of three new directors (Mika Grasso, Katharyn Field, and Jatinder Dhaliwal) designated by the Lender pursuant to a Revolving Loan Agreement, effective June 12, 2026. While the section also mentions the resignation of three prior directors, the principal disclosed action centers on the appointment of the New Directors with specified committee assignments and independence determinations. This represents a material change in board composition driven by lender control rights.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:03:39.161296+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6623,"accession_number":"0001021771-26-000091","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The Company entered into a $1,000,000 Revolving Loan Agreement with Bowery Group LLC on June 10, 2026, a material definitive agreement disclosed under Item 1.01. While this is a financing arrangement rather than a traditional M\u0026A transaction, it represents a material change of control indicator given the Lender's right to designate directors (referenced in Item 5.02), suggesting a significant shift in governance and financial control that would affect a reasonable investor's assessment of the registrant.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:03:39.161296+00:00","company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","filing_date":"2026-06-12"},{"id":6624,"accession_number":"0001021771-26-000091","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses the appointment of three new directors (Mika Grasso, Katharyn Field, and Jatinder Dhaliwal) designated by the Lender pursuant to a Revolving Loan Agreement, effective June 12, 2026. While the section also mentions the resignation of three prior directors, the principal disclosed action centers on the appointment of the New Directors with specified committee assignments and independence determinations. This represents a material change in board composition driven by lender control rights.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:03:39.161296+00:00","company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","filing_date":"2026-06-12"}]}